DTx Neuroglee raises $10 million to treat neurodegenerative diseases

DTx Neuroglee raises $10 million to treat neurodegenerative diseases

A Boston-based startup is looking to help treat neurodegenerative disease with a smartphone-based digital therapeutic called Neuroglee.

This morning the startup got a boost when it closed a $10 million Series A round led by Openspace Ventures with participation from EDBI, Eisai Co and individual investors. 

“Various techniques have been demonstrated to slow or improve cognitive impairment in Alzheimer’s disease,” Aniket Singh Rajput, CEO of Neuroglee, told MobiHealthNews in an email.

“While the majority of this work has been demonstrated in the hospital setting in inpatient programs, we had a dream of bringing that type of therapy to patients in their own homes – especially to those patients who aren’t near a clinical center of excellence with this type of program.

"We will now be able to do that by working with patients’ clinicians across the country via our virtual care and digital therapy solutions.”




Next Article

Did you find this useful?

Medigy Innovation Network

Connecting innovation decision makers to authoritative information, institutions, people and insights.

Medigy Logo

The latest News, Insights & Events

Medigy accurately delivers healthcare and technology information, news and insight from around the world.

The best products, services & solutions

Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.


© 2024 Netspective Media LLC. All Rights Reserved.

Built on Apr 23, 2024 at 3:40am